Influence of XPD and APE1
DNA repair gene polymorphism on bladder cancer susceptibility in North India.
modulates cellular responses to organophosphate pesticide-induced oxidative damage in non-small cell lung carcinoma A549 cells.
Apexian Pharmaceuticals is a biotechnology company dedicated to developing novel anti-cancer compounds that target the multiple functions of the APE1
Relationship of XRCC1, PARP1 and APE1
polymorphisms with efficacy of platinum-based chemotherapy for patients with advanced non-small cell lung cancer (in Chinese).
Zbadano wiele polimorfizmow typu SNP w genach kodujacych enzymy naprawy DNA, takie jak APE1
(apurinic/apyrimidinic endonuclease 1--endonukleaza miejsca apurynowego/apirymidynowego), hOGG1 (human 8-oxoguanine glycosylase--glikozylaza 8-oksyguaniny) czy XRCC1 (X-ray repair cross-complementing protein group 1--biaiko biorace udziai w naprawie DNA przez wycinanie zasad), ktore istotnie wplywaja na skutecznosc zapobiegania uszkodzeniom DNA indukowanym przez ksenobiotyki.
Abasic sites are repaired by APE1
to avoid mutagenic bypass, replication fork stalling, or conversion to double strand breaks.
Hu, "Senile cataract and genetic polymorphisms of APE1
, XRCC1 and OGG1," International Journal of Clinical and Experimental Pathology, vol.
Wu et al., "Polymorphisms in genes of APE1
, PARP1, and XRCC1: risk and prognosis of colorectal cancer in a northeast Chinese population," Medical Oncology, vol.
Seo, "A novel chemopreventive mechanism of selenomethionine: enhancement of APE1
enzyme activity via a Gadd45a, PCNA and APE1
protein complex that regulates p53-mediated base excision repair," Oncology Reports, vol.
Ren et al., "Upregulation of PD-L1 and APE1
is associated with tumorigenesis and poor prognosis of gastric cancer," Drug Design, Development and Therapy, vol.
Some of the potential dementia fighters now under review in NIH-funded research labs include saracatinib, a cancer drug that blocks Fyn, which is an enzyme associated with Alzheimer; microtubule stabilizing chemicals, which could help researchers get other useful drugs past the barrier that keeps most drugs out of the brain; MW181, a drug that fights brain inflammation; APE1
, an enzyme that helps brain cells repair DNA; and Citalopram, an antidepressant already on the market that might keep beta-amyloid plaques from coating neurons.